MARKET WIRE NEWS

Apogee Therapeutics Inc. (NASDAQ : APGE) Stock

MWN-AI** Summary

MWN-AI** Analysis

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.


Description


Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.


Quote


Last:$86.275
Change Percent: -1.47%
Open:$90
Close:$87.56
High:$91.9
Low:$85.935
Volume:437,444
Last Trade Date Time:06/05/2026 12:45:43 pm

Stock Data


Market Cap:$4,474,975,000
Float:36,961,244
Insiders Ownership:2.65%
Institutions:54
Short Percent:N/A
Industry:Biotechnology & Life Sciences
Sector:Healthcare
Website:https://www.apogeetherapeutics.com
Country:US
City:Waltham

Recent News Releases


Subscribe to Our Newsletter

**MWN-AI FAQ is based on asking OpenAI questions about Apogee Therapeutics Inc. (NASDAQ: APGE).

Link Market Wire News to Your X Account

Download The Market Wire News App